RECRUITINGPhase 2 / Phase 3INTERVENTIONAL
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)
About This Trial
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Who May Be Eligible (Plain English)
Who May Qualify:
Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.
Who Should NOT Join This Trial:
History of or suspected CMV disease within 6 months prior is excluded.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.
Exclusion Criteria:
History of or suspected CMV disease within 6 months prior is excluded.
Treatments Being Tested
DRUG
Letermovir
CMV prophylaxis
DRUG
Valganciclovir
Standard therapy for CMV prophylaxis
Locations (2)
NYP-Weill Cornell
New York, New York, United States
Columbia University/NYP Milstein Hospital
New York, New York, United States